---
title: "LADX.US (LADX.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/LADX.US/news.md"
symbol: "LADX.US"
name: "LADX.US"
parent: "https://longbridge.com/zh-CN/quote/LADX.US.md"
datetime: "2026-03-16T10:23:14.752Z"
locales:
  - [en](https://longbridge.com/en/quote/LADX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LADX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LADX.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/LADX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/LADX.US/news.md)


# LADX.US (LADX.US) — 相关新闻

### [LadRx Corporation | 10-Q: FY2025 Q1 EPS: USD -1.45](https://longbridge.com/zh-CN/news/240136784.md)
*2025-05-14T10:04:45.000Z*
### [LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th](https://longbridge.com/zh-CN/news/231543684.md)
*2025-03-12T13:06:30.000Z*
> LadRx Corporation (OTCQB: LADX) will present at the Virtual Life Science Investor Forum on March 13, 2025, at 3:00 PM ET

### [LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates | LADX Stock News](https://longbridge.com/zh-CN/news/222098615.md)
*2024-12-12T01:30:00.000Z*
> LadRx Corporation (OTCQB: LADX) is restarting its process to seek marketing approval for aldoxorubicin under the FDA’s 5

### [LadRx And ImmunityBio Agree To Terminate Aldoxorubicin License](https://longbridge.com/zh-CN/news/205479144.md)
*2024-06-04T01:46:44.000Z*
> LadRx and ImmunityBio have mutually agreed to terminate the license of aldoxorubicin, allowing LadRx to regain control. 

### [XOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPC](https://longbridge.com/zh-CN/news/105877746.md)
*2024-01-12T02:06:06.000Z*
> XOMA Corp. will pay a $1 million milestone payment to LadRx following the FDA's acceptance of Zevra Therapeutics' New Dr

### [XOMA To Make $1M Milestone Payment To LadRx, Reveals FDA Acceptance Of Zevra's Arimoclomol NDA Filing For Niemann-Pick Disease Type C](https://longbridge.com/zh-CN/news/105862752.md)
*2024-01-11T21:14:38.000Z*
> In June 2023, XOMA announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestone

### [LadRx Announces Reverse Stock Split Effective as of May 17, 2023](https://longbridge.com/zh-CN/news/88020460.md)
*2023-05-18T12:07:01.000Z*
> (marketscreener.com) LadRx Corporation , a biopharmaceutical innovator focused on research and development of life-savin

### [LadRx Announces Reverse Stock Split](https://longbridge.com/zh-CN/news/87296039.md)
*2023-05-10T12:09:02.000Z*
> (marketscreener.com) LadRx Corporation , a biopharmaceutical innovator focused on research and development of life-savin